Time to abandon traditional chemotherapy for acute promyelocytic leukaemia?

The Lancet Oncology

Volumn 16, Issue 13, 2015, Pages 1274-1275

  Ravandi, Farhad ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; RETINOIC ACID; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE;

ACUTE MYELOBLASTIC LEUKEMIA; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CARDIOTOXICITY; CONSOLIDATION CHEMOTHERAPY; DRUG EFFICACY; EVENT FREE SURVIVAL; FEASIBILITY STUDY; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HEART DISEASE; HIGH RISK PATIENT; HUMAN; HYPERBILIRUBINEMIA; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QTC INTERVAL; QUALITY OF LIFE; TREATMENT OUTCOME; FEMALE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; FEMALE; HUMANS; IDARUBICIN; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; OXIDES; TRETINOIN;

EID: 84954027736     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00210-7     Document Type: Note

References (11)

1. Wang ZY, Chen Z Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008, 111:2505-2515.
2. Ades L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood 2008, 111:1078-1084.
3. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001, 19:3852-3860.
4. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010, 116:3751-3757.
5. Ghavamzadeh A, Alimoghaddam K, Rostami S, et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol 2011, 29:2753-2757.
6. Mathews V, George B, Chendamarai E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol 2010, 28:3866-3871.
7. Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004, 101:5328-5335.
8. Iland HJ, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 2012, 120:1570-1580.
9. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009, 27:504-510.
10. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013, 369:111-121.
11. Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol 2015, published online Sept 15. http://dx.doi.org/10.1016/S1470-2045(15)00193-X.